Patient-Focused Drug Development Meeting, Part 1 (2016 Myotonic Annual Conference)

Myotonic community members living with DM, and their caregivers present on the impacts of DM on daily living, in response to specific questions posed by the Food and Drug Administration, which is in charge of reviewing and approving therapies in the U.S. Dr. Janet Woodcock, M.D., who leads all drug evaluation and research at the FDA, also provided remarks – at the 2016 DM Patient-Focused Drug Development meeting, a component of the 2016 Myotonic Annual Conference.

Home / Digital Academy / Patient-Focused Drug Development Meeting, Part 1 (2016 Myotonic Annual Conference)

© Myotonic. All rights reserved.